Physicians' Academy for Cardiovascular Education

Lp(a)

Recently added learning

Introduction: Lp(a), a new lipid frontier in CV risk management & target for therapy

10' education - Nov. 3, 2020 - Prof. Erik Stroes, MD

Is there a role for PCSK9 inhibition in patients with high Lp(a)?

10' education - Nov. 2, 2020 - Prof. Vera Bittner, MD - Online CME

Novel strategies to lower Lp(a)

10' education - Oct. 27, 2020 - Prof. Sam Tsimikas, MD - Online CME

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD

Why worry about high Lp(a) and how to assess Lp(a) levels?

10' education - Oct. 7, 2020 - Pia Kamstrup, MD, PhD - Online CME

Familial Hypercholesterolemia and Lp(a)

10' education - July 14, 2020 - Nick Nurmohamed, MD

Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)

10' education - May 26, 2020 - Prof. J. Wouter Jukema, MD - Leiden, The Netherlands

Assessing residual lipid risk with advanced testing

5' education - Feb. 17, 2020 - Samia Mora, MD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Are we ready for prime-time Lp(a) assay standardization?

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Santica Marcovina

LDL vs Lp(a) cholesterol: confounding

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Calvin Yeang, MD, PhD

Associations of Lp(a) with CV morbidity and mortality

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Pia Kamstrup, MD, PhD

Phase II data on Lp(a) lowering, followed by NHLBI recommendation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Sam Tsimikas

Entry of Lp(a) into the CV arena

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Florian Kronenberg, MD

Lp(a) apheresis and CVD risk modulation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Elisa Waldmann, MD

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD

Lp(a) and calcification in aortic stenosis

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Kang He Zheng, MD

Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction

3' education - May 29, 2019 - Maastricht. The Netherlands - Prof. Chapman, DSc

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands - Online CME

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

Lowering Lp(a) potently and safely with antisense technology

3' education - Nov. 20, 2018 - Sotirios Tsimikas, MD

PCSK9 inhibitors may represent the first therapeutic means to lower Lp(a)

3' education - June 29, 2018 - John Chapman - Paris, France

How much should Lp(a) be lowered to translate into meaningful CV benefit?

3' education - June 29, 2018 - Brian Ference, MD - Cambridge, UK

Advancing insights into Lp(a) as a causal factor in CVD

3' education - June 29, 2018 - John Chapman - Paris, France

Emerging approaches to dyslipidemia management beyond LDL-c

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Eliot Brinton, Salt Lake City, UT, USA

Lipoprotein metabolism & CV risk: a long road from understanding to treatment

10' education - Jan. 6, 2017 - Prof. John JP Kastelein, Amsterdam, The Netherlands

Emerging therapeutic areas in lipid management and CV disease

3' education - Mar. 16, 2017 - VBWG - ACC 2017 - Sotirios Tsimikas - La Jolla, CA, USA

PCSK9 inhibitors: From bench to bedside

10' education - Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

PCSK9, the short track road from discovery as drug target towards the clinic

10' education - Aug. 27, 2016 - ESC 2016, Rome - Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France

Surviving elevated Lp(a): a patient story from diagnosis to treatment

10' education - May 27, 2016 - Innsbruck, Germany - Sandra Revill Tremulis, MBA - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

A patient with elevated Lp(a): What is current clinical practice to manage this condition?

10' education - May 27, 2016 - Innsbruck, Germany - Prof. Klaus G. Parhofer, MD - University of Munich, Germany - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

The future perspectives for care for patients with high Lp(a)

10' education - May 27, 2016 - Innsbruck, Germany - Prof. Erik Stroes, MD PhD – Academic Medical Center, Amsterdam, The Netherlands - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

On demand 10" video

Introduction: Lp(a), a new lipid frontier in CV risk management & target for therapy

10' education - Nov. 3, 2020 - Prof. Erik Stroes, MD

Is there a role for PCSK9 inhibition in patients with high Lp(a)?

10' education - Nov. 2, 2020 - Prof. Vera Bittner, MD - Online CME

Novel strategies to lower Lp(a)

10' education - Oct. 27, 2020 - Prof. Sam Tsimikas, MD - Online CME

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD

Why worry about high Lp(a) and how to assess Lp(a) levels?

10' education - Oct. 7, 2020 - Pia Kamstrup, MD, PhD - Online CME

Familial Hypercholesterolemia and Lp(a)

10' education - July 14, 2020 - Nick Nurmohamed, MD

Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)

10' education - May 26, 2020 - Prof. J. Wouter Jukema, MD - Leiden, The Netherlands

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands - Online CME

Lipoprotein metabolism & CV risk: a long road from understanding to treatment

10' education - Jan. 6, 2017 - Prof. John JP Kastelein, Amsterdam, The Netherlands

PCSK9 inhibitors: From bench to bedside

10' education - Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

PCSK9, the short track road from discovery as drug target towards the clinic

10' education - Aug. 27, 2016 - ESC 2016, Rome - Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France

Surviving elevated Lp(a): a patient story from diagnosis to treatment

10' education - May 27, 2016 - Innsbruck, Germany - Sandra Revill Tremulis, MBA - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

A patient with elevated Lp(a): What is current clinical practice to manage this condition?

10' education - May 27, 2016 - Innsbruck, Germany - Prof. Klaus G. Parhofer, MD - University of Munich, Germany - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

The future perspectives for care for patients with high Lp(a)

10' education - May 27, 2016 - Innsbruck, Germany - Prof. Erik Stroes, MD PhD – Academic Medical Center, Amsterdam, The Netherlands - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

Introduction: Lp(a), a new lipid frontier in CV risk management & target for therapy

10' education - Nov. 3, 2020 - Prof. Erik Stroes, MD
Prof. Stroes gives an introduction to the symposium about different aspects of lipoprotein(a) (Lp(a)), that was held during the virtual ESC 2020 congress.

Prof. Stroes gives an introduction to the symposium about different aspects of lipoprotein(a) (Lp(a)), that was held during the virtual ESC 2020 congress.

Is there a role for PCSK9 inhibition in patients with high Lp(a)?

10' education - Nov. 2, 2020 - Prof. Vera Bittner, MD - Online CME
Prof. Bittner summarizes findings from post-hoc analyses of FOURIER and ODYSSEY OUTCOMES on the relationship between Lp(a) lowering by PCSK9i and CV risk.

Prof. Bittner summarizes findings from post-hoc analyses of FOURIER and ODYSSEY OUTCOMES on the relationship between Lp(a) lowering by PCSK9 inhibition and CV risk.

Novel strategies to lower Lp(a)

10' education - Oct. 27, 2020 - Prof. Sam Tsimikas, MD - Online CME
RNA therapeutics can reduce production of apo(a) in hepatocytes and thereby prevent assembly of Lp(a). This presentation provides an overview of phase 2 studies with antisense mediated Lp(a) lowering.

RNA therapeutics can reduce production of apo(a) in hepatocytes and thereby prevent assembly of Lp(a). This presentation provides an overview of phase 2 studies with antisense mediated Lp(a) lowering.

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD
Prof. Laufs discusses the role of triglycerides and Lp(a) in the context of residual risk.

Prof. Laufs discusses the role of triglycerides and Lp(a) in the context of residual risk.

Why worry about high Lp(a) and how to assess Lp(a) levels?

10' education - Oct. 7, 2020 - Pia Kamstrup, MD, PhD - Online CME
High Lp(a) levels are associated with increased risk of CV events. Pia Kamstrup presents the evidence from studies and in addition talks about challenges when determining Lp(a) levels.

High Lp(a) levels are associated with increased risk of CV events. Pia Kamstrup presents the evidence from studies and in addition talks about challenges when determining Lp(a) levels.

Familial Hypercholesterolemia and Lp(a)

10' education - July 14, 2020 - Nick Nurmohamed, MD
Nick Nurmohamed explains what Lp(a) is and how correction of LDL-c for Lp(a) reduces genetic testing for FH.

Nick Nurmohamed explains what Lp(a) is and how correction of LDL-c for Lp(a) reduces genetic testing for FH.

Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)

10' education - May 26, 2020 - Prof. J. Wouter Jukema, MD - Leiden, The Netherlands
Prof. Jukema explains the main principles for LDL-c-lowering therapy as described in the 2019 ESC/EAS guidelines and discusses results from several trials that investigated the role of Lp(a) on CV outcomes.

Prof. Jukema explains the main principles for LDL-c-lowering therapy as described in the 2019 ESC/EAS guidelines and discusses results from several trials that investigated the effect of Lp(a) on CV outcomes.

Assessing residual lipid risk with advanced testing

5' education - Feb. 17, 2020 - Samia Mora, MD
Which lipids/lipoproteins, besides LDL-c, play a role in determining CV risk and can help targeting therapy in those with residual lipid risk?

Which lipids/lipoproteins, besides LDL-c, play a role in determining CV risk and can help targeting therapy in those with residual lipid risk?

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD
Prof. Landmesser shows data that form the rationale behind new guideline recommendations, among which the lower LDL-c target for patients at very high risk.

Prof. Landmesser shows data that form the rationale behind new guideline recommendations, among which the lower LDL-c target for patients at very high risk.

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD
Erin Bohula explains which determinants of residual CV risk we nowadays know and presents study results on how to target these.

Erin Bohula explains which determinants of residual CV risk we nowadays know and presents study results on how to target these.

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME
Prof. Steg presents data of the ODYSSEY Outcomes trial in specific subgroups of ACS patients that benefit most from alirocumab therapy, and discusses the effect of this PCSK9 inhibitor by baseline Lp(a) levels.

Prof. Steg presents data of the ODYSSEY Outcomes trial in specific subgroups of ACS patients that benefit most from alirocumab therapy, and discusses the effect of this PCSK9 inhibitor by baseline Lp(a) levels.

Are we ready for prime-time Lp(a) assay standardization?

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Santica Marcovina
Prof. Marcovina emphasizes the importance of considering apo(a) size polymorphism when measuring Lp(a) levels in patients and discusses the Lp(a) Standardization Program.

Lp(a) meeting Prof. Marcovina emphasizes the importance of considering apo(a) size polymorphism when measuring Lp(a) levels in patients and discusses the Lp(a) Standardization Program.

LDL vs Lp(a) cholesterol: confounding

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Calvin Yeang, MD, PhD
Existing clinical LDL-c assays cannot distinguish LDL-c from Lp(a)-c. Dr. Yeang discusses how Lp(a)-c is included in LDL-c measurements and what the clinical impact of measuring Lp(a)-c can be.

Lp(a) meeting Existing clinical LDL-c assays cannot distinguish LDL-c from Lp(a)-c. Dr. Yeang discusses how Lp(a)-c is included in LDL-c measurements and what the clinical impact of measuring Lp(a)-c can be.

Associations of Lp(a) with CV morbidity and mortality

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Pia Kamstrup, MD, PhD
Pia Kamstrup shares data of two general population studies that reveal the effects of elevated Lp(a) levels on CV events, and effects of Lp(a) risk genotypes, which are consistent with Lp(a) being a causal risk factor for CVD.

Lp(a) meeting Pia Kamstrup shares data of two general population studies that reveal the effects of elevated Lp(a) levels on CV events, and effects of Lp(a) risk genotypes, which are consistent with Lp(a) being a causal risk factor for CVD.

Phase II data on Lp(a) lowering, followed by NHLBI recommendation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Sam Tsimikas
Prof. Tsimikas discusses the phase 2 apo(a)-LRx trial that evaluated Lp(a) lowering with an antisense oligonucleotide and presents NHLBI recommendations on Lp(a) lowering.

Lp(a) meeting Prof. Tsimikas discusses the phase 2 apo(a)-LRx trial that evaluated Lp(a) lowering with an antisense oligonucleotide and presents NHLBI recommendations on Lp(a) lowering.

Entry of Lp(a) into the CV arena

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Florian Kronenberg, MD
Small isoforms of Lp(a) are associated with high Lp(a) concentrations and increased CVD risk. The team of Kronenberg discovered a mutation in the Kringle-IV type 2 region of Lp(a), which has a modifying effect on Lp(a) levels and CVD risk.

Lp(a) meeting Small isoforms of Lp(a) are associated with high Lp(a) concentrations and increased CVD risk. The team of Kronenberg discovered a mutation in the Kringle-IV type 2 region of Lp(a), which has a modifying effect on Lp(a) levels and CVD risk.

Lp(a) apheresis and CVD risk modulation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Elisa Waldmann, MD
Elisa Waldmann shows prospective data on reduced CV event rates after regular Lp(a) apheresis in patients with high baseline Lp(a) levels and emphasizes the need of randomized controlled data.

Lp(a) meeting Elisa Waldmann shows prospective data on reduced CV event rates after regular Lp(a) apheresis in patients with high baseline Lp(a) levels and emphasizes the need of randomized controlled data.

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD
The prevalence of clinical FH was investigated in the Copenhagen General Population Study with adjustment for the cholesterol content in Lp(a). Prof. Nordestgaard shares possible ways to interpret these results.

Lp(a) meeting The prevalence of clinical FH was investigated in the Copenhagen General Population Study with adjustment for the cholesterol content in Lp(a). Prof. Nordestgaard shares possible ways to interpret these results.

Lp(a) and calcification in aortic stenosis

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Kang He Zheng, MD
Zheng shows study results on the pathophysiological role of elevated Lp(a) and oxidized phospholipids levels in progression of aortic stenosis.

Lp(a) meeting Zheng shows study results on the pathophysiological role of elevated Lp(a) and oxidized phospholipids levels in progression of aortic stenosis.

Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction

3' education - May 29, 2019 - Maastricht. The Netherlands - Prof. Chapman, DSc
Prof. Chapman lists the newest findings on the associations of Lp(a) levels, PCSK9 inhibitors and CV risk, based on new analyses of the FOURIER and ODYSSEY OUTCOMES trials.

EAS 2019 Prof. Chapman lists the newest findings on the associations of Lp(a) levels, PCSK9 inhibitors and CV risk, based on new analyses of the FOURIER and ODYSSEY OUTCOMES trials.

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands - Online CME
Currently only small numbers of ASCVD patients achieve target LDL-c levels due to certain issues surrounding lipid lowering therapy. Prof. John Kastelein discusses the role of PCSK9 inhibition and future perspectives on lipid lowering.

Currently only small numbers of ASCVD patients achieve target LDL-c levels due to certain issues surrounding lipid lowering therapy. Prof. John Kastelein discusses the role of PCSK9 inhibition and future perspectives on lipid lowering.

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

AHA 2018 - Chicago, IL, USA

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD
In the ANITSCHKOW study, patients with very high Lp(a) were treated with evolocumab 420 mg once monthly. The 14% lowering in Lp(a) was not sufficient to eliminate the inflammatory stimulans induced by Lp(a).

AHA 2018 In the ANITSCHKOW study, patients with very high Lp(a) were treated with evolocumab 420 mg once monthly. The 14% lowering in Lp(a) was not sufficient to eliminate the inflammatory stimulans induced by Lp(a).

Lowering Lp(a) potently and safely with antisense technology

AHA 2018 - Chicago, IL, USA

3' education - Nov. 20, 2018 - Sotirios Tsimikas, MD
Lp(a) is a highly prevalent risk factor, with to date no therapy to lower its levels. A phase 2b study now shows that an antisense oligonucleotide potently lowers production of Lp(a), to optimal levels.

AHA 2018 Lp(a) is a highly prevalent risk factor, with to date no therapy to lower its levels. A phase 2b study now shows that an antisense oligonucleotide potently lowers production of Lp(a), to optimal levels.

PCSK9 inhibitors may represent the first therapeutic means to lower Lp(a)

3' education - June 29, 2018 - John Chapman - Paris, France
In high Lp(a)-associated CV risk patients, reduction of Lp(a) with PCSK9 inhibition lowered this risk, even at very low LDL-c levels.

In high Lp(a)-associated CV risk patients, reduction of Lp(a) with PCSK9 inhibition lowered this risk, even at very low LDL-c levels.

How much should Lp(a) be lowered to translate into meaningful CV benefit?

3' education - June 29, 2018 - Brian Ference, MD - Cambridge, UK
Trials on lowering Lp(a) have thusfar failed to show a CV outcome benefit. Brian Ference describes a more informative approach to look at Lp(a) data to identify who may benefit from Lp(a)-lowering therapy.

Trials on lowering Lp(a) have thusfar failed to show a CV outcome benefit. Brian Ference describes a more informative approach to look at Lp(a) data to identify who may benefit from Lp(a)-lowering therapy.

Advancing insights into Lp(a) as a causal factor in CVD

3' education - June 29, 2018 - John Chapman - Paris, France
Elevated Lp(a) is now officially considered a genetically determined risk factor for CVD in the USA. Chapman summarizes how Lp(a) is atherogenic and how novel therapies may target this process.

Elevated Lp(a) is now officially considered a genetically determined risk factor for CVD in the USA. Chapman summarizes how Lp(a) is atherogenic and how novel therapies may target this process.

Emerging approaches to dyslipidemia management beyond LDL-c

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Eliot Brinton, Salt Lake City, UT, USA
Several novel targets have been discovered and new lipid-modifying therapies are being developed to prevent CVD, beyond LDL-c.. Elliot Brinton discusses several of these, including omega-3 prescriptions, pemafibrate, apoC3, Lp(a), and shares the first trial results.

VBWG at ACC 2018 Several novel targets have been discovered and new lipid-modifying therapies are being developed to prevent CVD, beyond LDL-c. Elliot Brinton discusses several of these, including omega-3 prescriptions, pemafibrate, apoC3, Lp(a), and shares the first trial results.

Lipoprotein metabolism & CV risk: a long road from understanding to treatment

10' education - Jan. 6, 2017 - Prof. John JP Kastelein, Amsterdam, The Netherlands
Prof. John Kastelein describes 3 major disturbances in lipoprotein metabolism contributing to CV risk. Novel therapies are being developed to address residual risk after LDL-c eradication.

Prof. John Kastelein describes 3 major disturbances in lipoprotein metabolism contributing to CV risk. Novel therapies are being developed to address residual risk after LDL-c eradication.

Emerging therapeutic areas in lipid management and CV disease

3' education - Mar. 16, 2017 - VBWG - ACC 2017 - Sotirios Tsimikas - La Jolla, CA, USA
Sotirios Tsimikas summarises the rationale of innovative therapeutic approaches targeting Lp(a), ApoC3 or ATP citric lyase and in what stage of clinical testing they currently are.

VBWG ACC 2017 Sotirios Tsimikas summarises the rationale of innovative therapeutic approaches targeting Lp(a), ApoC3 or ATP citric lyase and in what stage of clinical testing they currently are.

PCSK9 inhibitors: From bench to bedside

10' education - Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA
Prof. Gilles Lambert describes the development since the discovery in 2002 of PCSK9 until the results of outcome trials with a PCSK9 inhibitor in 2017.

PCSK9 Expert Opinions Prof. Gilles Lambert describes the development of PCSK9 inhibitors since the discovery in 2002 of PCSK9 as a circulating protein targeting the LDL receptor for degradation. Now in 2017, results of outcome trials with a PCSK9 inhibitor are available.

PCSK9, the short track road from discovery as drug target towards the clinic

10' education - Aug. 27, 2016 - ESC 2016, Rome - Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France

Gilles Lambert, MD describes the discovery and biology of PCSK9 and the effect of PCSK9-inhibitors on LDL-C and Lp(a).

Surviving elevated Lp(a): a patient story from diagnosis to treatment

10' education - May 27, 2016 - Innsbruck, Germany - Sandra Revill Tremulis, MBA - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS
A patient's perspective of someone with elevated Lp(a), and consequently a high CV risk, despite a healthy lifestyle

Sandra Revill Tremulis, founder of the Lipoprotein(a) Foundation, shares her experiences as a patient with elevated Lp(a), and consequently a high CV risk, despite a healthy lifestyle.

A patient with elevated Lp(a): What is current clinical practice to manage this condition?

10' education - May 27, 2016 - Innsbruck, Germany - Prof. Klaus G. Parhofer, MD - University of Munich, Germany - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS
Current clinical practice to treat patients with elevated Lp(a) to reduce CV risk

Prof. Klaus G. Parhofer (Munich, Germany) discusses the effects of currently available therapies to treat individuals with elevated Lp(a) levels, and shares a treatment algorithm to lower CV risk in these patients.

The future perspectives for care for patients with high Lp(a)

10' education - May 27, 2016 - Innsbruck, Germany - Prof. Erik Stroes, MD PhD – Academic Medical Center, Amsterdam, The Netherlands - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS
Lp(a) levels are hardly responsive to currently available drugs, but novel therapeutic options are in development to lower this CV risk factor.

Individuals with elevated Lp(a) levels are at increased CV risk. Lp(a) levels are hardly responsive to currently available medication, so new therapeutic strategies are needed. Prof. Stroes summarises our understanding of Lp(a)-induced atherogenesis and how this may be targeted with novel therapies.